The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions, Dig Dis Sci, vol.62, pp.833-875, 2017. ,
Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease, Aliment Pharmacol Ther, vol.39, pp.447-58, 2014. ,
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease, JAMA, vol.318, pp.1679-86, 2017. ,
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, vol.142, pp.63-70, 2012. ,
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation, Scand J Gastroenterol, vol.51, pp.196-202, 2016. ,
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission, Clin Gastroenterol Hepatol, vol.16, p.2, 2018. ,
, Accepted Article
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study, Clin Gastroenterol Hepatol, vol.14, p.1, 2016. ,
Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis, Arthritis Rheumatol, vol.69, pp.108-121, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01980809
Therapeutic drug monitoring is predictive of loss of response after deescalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission, Clin Res Hepatol Gastroenterol, vol.40, pp.90-98, 2016. ,
Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring, Aliment Pharmacol Ther, vol.49, pp.147-54, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-01998041
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease, Gastroenterology, vol.148, pp.1320-1329, 2015. ,
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study, Inflamm Bowel Dis, vol.24, pp.1745-54, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01821736
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease, Inflamm Bowel Dis, vol.23, pp.650-60, 2017. ,
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice, Aliment Pharmacol Ther, vol.42, pp.529-568, 2015. ,
A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease, Eur J Clin Pharmacol, vol.71, pp.1541-1543, 2015. ,
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis, Eur J Clin Pharmacol, vol.65, pp.1211-1239, 2009. ,
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis, Br J Clin Pharmacol, vol.79, pp.286-97, 2015. ,
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clin Gastroenterol Hepatol, vol.14, pp.348-54, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01668509
The underlying inflammatory chronic disease influences infliximab pharmacokinetics, MAbs, vol.8, pp.1407-1423, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01980816
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, Br J Clin Pharmacol, vol.78, pp.118-146, 2014. ,